A Phase 1, Randomized, Double-Blind, Cross-Over, Vehicle-Controlled, Single-Dose Study To Characterize The Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) In Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 14 May 2014
Price : $35 *
At a glance
- Drugs P 1037 (Primary)
- Indications Chronic obstructive pulmonary disease; Cystic fibrosis
- Focus Pharmacodynamics
- Sponsors Gilead Sciences
- 19 Sep 2013 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 21 Aug 2013 Planned end date changed from 1 Jun 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 21 Aug 2013 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.